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Objectives The aims of this study were to determine the spectrum and prevalence of “background genetic noise” in the ar-
rhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC) genetic test and to determine genetic associa-
tions that can guide the interpretation of a positive test result.
Background ARVC is a potentially lethal genetic cardiovascular disorder characterized by myocyte loss and fibrofatty tissue
replacement of the right ventricle. Genetic variation among the ARVC susceptibility genes has not been system-
atically examined, and little is known about the background noise associated with the ARVC genetic test.
Methods Using direct deoxyribonucleic acid sequencing, the coding exons/splice junctions of PKP2, DSP, DSG2, DSC2,
and TMEM43 were genotyped for 93 probands diagnosed with ARVC from the Netherlands and 427 ostensibly
healthy controls of various ethnicities. Eighty-two additional ARVC cases were obtained from published reports,
and additional mutations were included from the ARVD/C Genetic Variants Database.
Results The overall yield of mutations among ARVC cases was 58% versus 16% in controls. Radical mutations were hosted
by 0.5% of control individuals versus 43% of ARVC cases, while 16% of controls hosted missense mutations versus a
similar 21% of ARVC cases. Relative to controls, mutations in cases occurred more frequently in non-Caucasians, localized
to the N-terminal regions of DSP and DSG2, and localized to highly conserved residues within PKP2 and DSG2.
Conclusions This study is the first to comprehensively evaluate genetic variation in healthy controls for the ARVC susceptibil-
ity genes. Radical mutations are high-probability ARVC-associated mutations, whereas rare missense mutations
should be interpreted in the context of race and ethnicity, mutation location, and sequence conservation.
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Distinguishing ARVC Mutations June 7, 2011:2317–27Arrhythmogenic right ventricu-
lar cardiomyopathy/dysplasia
(ARVC) is a heritable cardiac
disease characterized by fibro-
fatty replacement of the right
ventricle, with a prevalence of 1
in 1,000 to 5,000 individuals
(1,2). It is a notable cause of
sudden cardiac death (SCD) sec-
ondary to fatal ventricular ar-
rhythmias, and sudden death is a
common first manifestation of the
disease (3). Despite its name,
ARVC can involve the left ventri-
cle in addition to the right and is
not necessarily arrhythmogenic
(4). This variable clinical course
may include: 1) a subclinical phase
with concealed structural abnor-
malities, during which the affected
patient may present with SCD as
the sentinel manifestation of the
isease; 2) an overt electrical disorder with palpitations and
yncope due to tachyarrhythmias stemming from the right
entricle; and 3) severe right ventricular or biventricular failure
equiring cardiac transplantation or resulting in death (5).
See page 2328
Roughly one-half of all ARVC is recognized as familial,
with an autosomal dominant inheritance as well as incomplete
penetrance and variable expressivity. To date, mutations in
several ARVC susceptibility genes that encode essential des-
mosomal proteins have been identified: PKP2-encoding pla-
kophilin 2, DSP-encoding desmoplakin, DSG2-encoding
esmoglein 2, DSC2-encoding desmocollin 2, JUP-
ncoding plakoglobin, and TMEM43-encoding transmem-
rane protein 43 (4). Desmosomes, also known as macula
dherens, are macromolecular cellular structures composed
f plasma membrane proteins involved in linking intracel-
ular intermediate filaments into a cell-spanning network,
llowing effective transmission of force across cells. It is
elieved that functional deficits in these proteins imparted
y genetic mutations result in cardiocyte detachment and
ell death, while subsequent inflammation results in fibro-
atty remodeling. In addition, it has been proposed that
ltered expression of ARVC susceptibility genes, specifically
SP, might lead to altered Wnt/b-catenin and Tcf/Lef1
ignaling, causing the fibrofatty remodeling and SCD pre-
isposition of ARVC (6).
Although nondesmosomal genes have been identified as
are causes of ARVC, the 3 desmosomal genes PKP2, DSP,
nd DSG2 harbor the majority of identified mutations,
ccounting for approximately 40% of ARVC cases in studies
Abbreviations
and Acronyms
ARVC  arrhythmogenic
right ventricular
cardiomyopathy/dysplasia
cDNA  coding
deoxyribonucleic acid
del  deletion
DNA  deoxyribonucleic
acid
DSC  desmocollin
DSG  desmoglein
DSP  desmoplakin
IVS  intervening sequence
JUP  junction plakoglobin
PKP  plakophilin
SCD  sudden cardiac
death
TMEM  transmembrane
proteinrom the Netherlands (7,8), Italy (9), and the United States a10). In particular, PKP2 represents the most common gene
utated in ARVC, with a prevalence ranging from 40%
identified as the sole cause of ARVC in the cohort [3,7]) to
pproximately 10% (9). The variable phenotypic expression
f this disease and the proclivity for inherited SCD risk
ake the identification of pathogenic disease biomarkers
ritical.
Recently, understanding of the genetic causes of ARVC
as matured from the research bench to a clinically available
ommercial genetic test with an estimated yield of approx-
mately 50% in patients with a likely diagnosis of ARVC
11). As with other clinical tests, a true understanding of the
xtent and spectrum of genetic variation found in a healthy
opulation is necessary for correct interpretation. Although
ignificant research has been dedicated to identifying patho-
enic mutations, little is known about the background
enetic variation in genes constituting the clinically available
RVC genetic tests. Understanding this signal-to-noise
atio is critical to determining whether an identified variant
f undetermined or uncertain significance might be the
iomarker responsible for disease in the proband or whether
t is a rare genetic variant with no relevance to the disease
tate. To this end, we sought to determine the spectrum and
revalence of background genetic variation that would meet
he criteria of a “mutation” on the ARVC genetic test and
o use this information to guide interpretation of a positive
enetic test result.
ethods
tudy cohorts. From 1997 to 2007, patients with ARVC
ere referred to the Academic Medical Center in Amster-
am, the University Medical Center Groningen in Gro-
ingen, and the University Medical Center Utrecht in
trecht, the Netherlands, for comprehensive ARVC ge-
etic testing after receipt of written informed consent. For
ach proband, a history and physical examination, 12-lead
lectrocardiography, 24-h Holter monitoring, exercise test-
ng, and 2-dimensional transthoracic echocardiography
ere conducted, as described previously (7,8).
To maximize the pre–genetic test possibility that a
ase-derived mutation is pathogenic, 93 “clinically definite,”
nrelated cases were used for this study. ARVC diagnosis
as based on the 2010 update (12) of the 1994 diagnostic
riteria of the Task Force of the European Society of
ardiology/International Society and Federation of Cardi-
logy (13). Similarly, 427 unrelated, ostensibly healthy
ubjects from various racial and ethnic backgrounds were
ubjected to ARVC genetic testing by Transgenomic Inc.
New Haven, Connecticut). These control individuals were
olunteers recruited and genotyped by Transgenomic Inc. as
art of the clinical ARVC genetic test validation process. At
he time of genotyping, ethnicity, sex, and age at diagnosis
r genotyping, as appropriate, were recorded for each case
nd control subject.
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June 7, 2011:2317–27 Distinguishing ARVC MutationsTo expand the spectrum of ARVC case mutations, 82
ARVC index cases genotyped in a recent U.S. ARVD/C
Registry (Baltimore, Maryland) study by den Haan et al.
(10) were included, yielding a combined ARVC case cohort
of 175 probands from the Netherlands and the United
States. In addition, for analysis of linear topology and
primary sequence species conservation, mutations from the
ARVD/C Genetic Variants Database (14) (University
Medical Center Groningen, Groningen, the Netherlands)
were incorporated.
Genetic analysis. The genomic deoxyribonucleic acid
(DNA) of all 427 controls and 93 Dutch cases was analyzed
for mutations in the translated exons and the splice site
regions of the major ARVC susceptibility genes: PKP2-
encoding plakophilin 2, DSP-encoding desmoplakin,
DSG2-encoding desmoglein 2, DSC2-encoding desmocol-
lin 2, and TMEM43-encoding transmembrane protein 43.
ARVC cases were additionally genotyped for JUP-encoding
junction plakoglobin (also known as PKGB); however,
because this gene was not genotyped for control subjects, it
was excluded from statistical comparison. Among the 93
Dutch cases, identified mutations were absent in 400
reference alleles derived from unrelated, ostensibly healthy,
ethnically matched Dutch volunteers. ARVC cases from the
U.S. ARVD/C Registry were genotyped for all genes above
with the exception of TMEM43, and all mutations were
bsent in 400 reference alleles derived from unrelated,
stensibly healthy, ethnically matched volunteers (Coriell
nstitute for Medical Research, Camden, New Jersey).
utation analyses were performed using polymerase chain
eaction followed by automated DNA sequencing.
enetic variant and mutation interpretation. Genetic
ariants predicted to alter the coding protein, through
issense alteration of a codon, alteration of the canonical
plice site, both in-frame and frame-shift insertion or
eletion mutations, or nonsense mutations resulting in a
remature truncation, were identified for this study. Any
uch variant observed in only ARVC cases and absent in
oth the ethnically-matched controls as well as the 427-
ontrol cohort, or a variant uniquely identified in 1 control
ohort subject, was annotated as a “mutation.” Importantly,
he designation of “mutation” herein is not meant to imply
athogenicity or even functional relevance to the respective
rotein. Rather, these are variants that, had they been
iscovered during the course of a clinical ARVC genetic
est, would be considered a possible pathogenic variant.
utations were classified using standard nomenclature.
n-frame and frame-shift insertions and deletions, splice
unction, and nonsense mutations were designated as “rad-
cal” mutations. As with the designation of “mutation,” the
esignation of “radical” is not meant to imply disease
athogenicity but rather to serve as a descriptor for analysis
f a class of mutations.
rimary sequence and species conservation analysis.
dentified mutations were overlaid on the linear protein
opology of each of the ARVC-associated gene products.The linear topology was annotated with known binding or
functional domains, motifs, and predicted secondary struc-
ture regions from published reports (15,16) as well as the
UniProtKB/Swiss-Prot databank (17). Sequence conserva-
tion analysis was similarly conducted using primary se-
quences from the University of California Santa Cruz
Genome Browser (18). To calculate the degree of conser-
vation of individual residues across species, primary se-
quences from 44 species, including primates, other placental
mammals, and nonmammalian vertebrates, were aligned.
Degree of nonidentity was determined by calculating the
number of primary sequences harboring an amino acid not
identical to the human residue at that location
(substitution).
Statistical analysis. Statistical analysis used the Fisher
exact test and 2-sided t tests, as appropriate, with a
threshold of significance of p  0.05. Variance was ex-
pressed as mean  SD. Sequencing conservation scores
were analyzed using Wilcoxon nonparametric 2-sample
tests. Due to a lack of ARVC cases matched by race or
ethnicity, statistical comparisons between ARVC cases and
non-Caucasian controls were not conducted.
Results
Study cohorts. Among the patients referred to the Dutch
university medical centers, 93 index cases met the criteria for
a “definite” diagnosis of ARVC according to the 2010
ARVC task force criteria (12,13,19). This Dutch Caucasian
cohort was 29% female, with an average age at diagnosis of
37  14 years. These cases were combined with the 82
ARVC cases of North American Caucasian subjects from
the U.S. ARVD/C Registry study cohort (10) (42% female,
diagnosed at 34 13 years) to yield a combined ARVC case
cohort of 175 probands, 35% female, with an average age at
diagnosis of 35  14 years.
The control cohort consisted of 427 unrelated, ostensibly
healthy subjects from various racial and ethnic backgrounds,
including 103 Caucasian-American (24.1%), 124 Asian
(29.0%), 110 African (25.8%), 42 Hispanic or Latino
(9.8%), 4 American-Indian (0.94%), and 12 multiracial
subjects (2.8%). There were 32 subjects (7.5%) from a
variety of other racial and ethnic backgrounds. To be
included in a specific racial or ethnic group, each subject
must have reported 4 grandparents from the same group,
while multiracial subjects had 1 or more grandparents of
different racial or ethnic origin. This cohort was 50.1%
female, with an average age at genotyping of 41  15 years.
The cohort demographics for this study are summarized in
Table 1.
Mutation spectrum and prevalence by cohort. Compre-
hensive genetic interrogation of the control and ARVC case
cohorts identified mutations in both cohorts. As demon-
strated in Figure 1, among the ostensibly healthy, cosmo-
politan control cohort, 69 of 427 subjects (16.2%) hosted
genetic variants that met our criteria to be considered rare
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Distinguishing ARVC Mutations June 7, 2011:2317–27“mutations,” creating what would have been annotated as a
possible “positive” ARVC genetic test result had the subject
been an ARVC case. Although not meant to imply patho-
genicity, we used this label for the purposes of further
analysis of background genetic variation. Among these
control cohort mutations, 19.7% localized to PKP2, 32.9%
in DSP, 21.1% in DSG2, 14.5% in DSC2, and 11.8% in
MEM43.
To test the hypothesis that the frequency of mutations
ound in control subjects reflected random genetic variabil-
ty, we compared the frequency of mutations with the
elative size of the coding deoxyribonucleic acid (cDNA) for
Figure 1 Prevalence of Mutations
in Control and ARVC Cohorts
(A) Pie charts of the percent of mutation-positive subjects within the control
(white) and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC)
(blue) cohorts separated from mutation-negative subjects (yellow) of each
respective cohort. (B) Pie chart of the percents of mutations found in each of
the ARVC-associated genes among mutation-positive cases in the control (left)
and ARVC (right) cohorts. JUP was not genotyped in controls, and TMEM43
was not genotyped in the U.S. ARVD/C Registry component of the ARVC case
cohort.
Study Cohort DemographicsTable 1 Study Cohort Demographics
Demographic
ARVC
Controls
Dutch
den Haan
et al. (10) Combined
Transgenomic
Inc.
Total 93 82 175 427
Caucasian 93 82 175 103
Asian 0 0 0 124
African 0 0 0 110
Hispanic/Latino 0 0 0 42
American Indian 0 0 0 4
Multiracial 0 0 0 12
Other 0 0 0 32
Female 29.00% 41.98% 35.06% 50.11%
Age (yrs) 37 14 34 13 35 14 41 15
Data are expressed as n, %, or mean  SD.
ARVC  arrhythmogenic right ventricular cardiomyopathy/dysplasia.ach of the genes. The 4,439 nucleotides that constitute the
DNA of PKP2 represent approximately 15.7% of the total
DNA for the ARVC-associated genes and approximately
9.7% of the mutations identified in controls localized to
KP2. Likewise, the frequencies of control mutations in
SP, DSG2, DSC2, and TMEM43 were similar to their
espective relative cDNA size (Table 2).
In contrast, ARVC cases had an overall yield of 58.3%,
ith 102 of 175 subjects hosting mutations absent in at least
00 reference alleles. Among the mutation-positive ARVC
ases, 78.4% of the mutations localized to PKP2, 2.7% to
SP, 13.5% to DSG2, 3.6% to DSC2, 0.9% to JUP, and
.9% to TMEM43. A summary of the genetic variants
dentified in the ARVC and control cohorts is listed in
nline Tables 1 and 2.
As shown in Figure 2, while there was an approximately
.5-fold higher genetic test yield for ARVC cases than
ontrols (58.3% vs. 16.2%, p  5  1024), approximately
1 in 6 healthy subjects genotyped met the criteria for a
mutation and a positive ARVC genetic test result. This
Relative Coding DNA LengthV rsus Mutation Frequ cyTable 2 Relativ Coding DNA LengthVersus Mutation Frequency
Gene
cDNA Size
(Nucleotides) Total
Control
Mutations Mutations
PKP2 4,439 15.7% 19.7% 78.4%
DSP 9,796 34.6% 32.9% 2.7%
DSG2 5,652 19.9% 21.1% 13.5%
DSC2 5,124 18.1% 14.5% 3.6%
TMEM43 3,341 11.8% 11.8% 0.9%
ARVC arrhythmogenic right ventricular cardiomyopathy/dysplasia; cDNA  coding deoxyribonu-
cleic acid; DNA  deoxyribonucleic acid.
Figure 2 Prevalence of Radical, Missense,
and Multiple Mutations
Bar graph depicting the number and percent of the control (white) and arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia (ARVC) case (blue) cohorts
hosting mutations. The overall yield of the genetic test (positive) was divided
into radical mutations, missense mutations, and subjects hosting more than 1
mutation (multiple). Numbers within bars denote number of subjects positive
for the respective mutation type in each cohort.
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June 7, 2011:2317–27 Distinguishing ARVC Mutationsso-called background genetic variation was largely missense
mutations, as only 2 of 427 control subjects (0.47%) hosted
radical mutations versus 75 of 175 ARVC cases (42.9%)
(p  9.8  1044), while 68 of 427 controls (15.9%) hosted
missense mutations versus 36 of 175 ARVC cases (20.6%)
(p  NS). The 2 radical mutations found in 2 control
subjects were PKP2-IVS5-1GA and DSP-S2843-
R2846del. A small percent of control subjects hosted 2 or
more mutations (9 of 427, 2.11%) compared with a higher
percent of ARVC cases (12 of 175, 6.86%; p  0.0065).
Among these subjects, 2 of 175 ARVC cases (1.1%) hosted
3 mutations, while no subjects in the control cohort had
more than 2 mutations.
Mutation spectrum and prevalence by race and ethnicity. To
determine whether there were race-specific or ethnicity-
specific differences in mutation type or prevalence, particu-
larly among missense mutations, we determined the fre-
quency of mutations among Caucasian and non-Caucasian
control subpopulations. Although the yield of mutations
in control subjects was 16.2% overall, mutations in non-
Caucasian subjects occurred at a higher frequency than in
Caucasian control subjects (19.44% vs. 5.83%, respectively,
p  0.003). Specifically, as shown in Figure 3, ostensibly
healthy Caucasian subjects had a much lower rate of
missense mutations (6 of 103, 5.83%) than non-Caucasian
control subjects (63 of 324, 19.4%; p  0.0007). This was
also lower than the overall prevalence of missense mutations
among the Dutch and North American Caucasian ARVC
cases (36 of 175, 20.6%; p  0.0009). The prevalence of
radical mutations across Caucasian and non-Caucasian
subsets of the control cohort was extremely small (0% and
Figure 3 Prevalence of Mutations in
Caucasian and Non-Caucasian Subjects
Bar graph of the number and percent of the arrhythmogenic right ventricular
cardiomyopathy/dysplasia (ARVC) (blue background) and control (white back-
ground) subjects hosting radical (no lines) or missense (diagonal lines) muta-
tions. Mutations identified in controls were subdivided into Caucasian and non-
Caucasian ostensibly healthy individuals. Numbers within bars denote number
of subjects positive for the respective mutation type in each cohort and cohort
subset.0.62%, respectively).Mutation spectrum and prevalence by gene. To deter-
mine whether the high background rate of genetic vari-
ation might be gene specific, as well as race or ethnicity
specific, we next calculated the percent of mutation-
positive subjects for each gene within the control cohort,
both Caucasian and non-Caucasian subsets, and the ARVC
cohort (Figs. 4 and 5). As demonstrated in Figure 4A, there
was a higher percent of subjects in the ARVC cohort
(49.7%) with mutations in PKP2 than in Caucasian controls
(0.97%, p  2.7  1021). While 4.32% of non-Caucasian
ontrols hosted mutations in PKP2, statistical comparison
ith the ARVC cases could not be conducted, because of
lack of non-Caucasian ARVC cases available in this
tudy. This difference in mutation frequency largely
eflects a higher percent of radical mutations in the
RVC cases (42.3%) than among either the Caucasian
ontrols (0%, p  8.1  1019) or the non-Caucasian
controls (0.31%). There was also a significantly higher
percent of PKP2 missense mutations in ARVC cases
(9.71%) than in Caucasian controls (0.97%, p  0.005),
hile 4.01% of non-Caucasian controls hosted PKP2
issense mutations.
Whereas mutations localizing to PKP2 were more prev-
lent in ARVC cases than Caucasian controls, the preva-
ence of mutations localizing to DSP demonstrated no
tatistical difference between ARVC cases and Caucasian
ontrol subjects (6.17% vs. 1.71%, respectively) (Fig. 4B).
he prevalence of mutations in healthy non-Caucasian
ontrol subjects was 6.48%. As shown in Figure 4C, a
igher percent of ARVC cases hosted mutations in DSG2
ompared to Caucasian controls (8.57% vs. 1.94%, p 
.05), while there was no difference between the back-
round genetic variation rate of non-Caucasians and ARVC
ases. This difference was due to an overrepresentation of
issense mutations among cases (8.00%) compared with
aucasians (1.94%, p  0.05).
There was no discernible difference in the percent of
atients with DSC2 (Fig. 5A) or TMEM43 (Fig. 5B)
mutations between the ARVC and both control subcohorts,
although the overall prevalence of mutations in these genes
was low.
Founder mutations. Although the ARVC case cohort
analyzed was composed of unrelated probands, we noted
several mutations that were found in multiple ARVC cases
that were absent in control subjects. To determine whether
these potential founder mutations affected the overall yield
of genetic testing among these ARVC cases, we identified
and reanalyzed the cohort yield excluding these potential
founder mutations: PKP2-IVS10-1GC, which was iden-
tified in 13 ARVC cases (4 Dutch), PKP2-C796R mutation
in 9 cases (all Dutch), and the PKP2-R79X nonsense
mutation in 8 cases (6 Dutch). When each of these potential
founder mutations was removed from the 2 ARVC cohorts,
the overall yield of mutations in the ARVC cases dropped
from 58.3% to 49.7% (63.4% to 43.0% in the Dutch ARVC
cohort and 52.4% to 39.0% in the North American ARVC
2322 Kapplinger et al. JACC Vol. 57, No. 23, 2011
Distinguishing ARVC Mutations June 7, 2011:2317–27cohort). As each of these potential founder mutations
localized to PKP2, exclusion of these mutations reduced the
PKP2-specific yield from 49.7% to 32.6% (53.8% to 33.3%
in the Dutch ARVC cohort and 45.1% to 31.7% in the
Figure 4 Prevalence of Mutations in PKP2, DSP, and DSG2
Bar graph depicting the number and percent of the Caucasian control (white), non
cardiomyopathy/dysplasia (ARVC) case (blue) cohorts hosting mutations in PKP2
into radical mutations, missense mutations, and subjects hosting more than 1 mu
tion in the respective gene in each cohort. *p  0.05; **p  0.01; ***p  0.00
Figure 5 Prevalence of Mutations in DSC2 and TMEM43
Bar graph depicting the number and percent of the Caucasian control (white), non
cardiomyopathy/dysplasia (ARVC) case (blue) cohorts hosting mutations in DSC2
radical mutations, missense mutations, and subjects hosting more than 1 mutatio
the respective gene in each cohort. *TMEM43 was not genotyped in the U.S. ARVNorth American ARVC cohort) while not altering other
ARVC gene frequencies.
Mutation “hot spots” in desmoplakin and desmoglein 2. On
the basis of the identification of key binding and functional
asian control (white with cross-hatching), and arrhythmogenic right ventricular
P (B), and DSG2 (C). The overall yield of the genetic test (positive) was divided
(multiple). Numbers within bars denote number of subjects positive for a muta-
asian control (white with cross-hatching), and arrhythmogenic right ventricular
d TMEM43 (B). The overall yield of the genetic test (positive) was divided into
ltiple). Numbers within bars denote number of subjects positive for a mutation in
egistry component of the ARVC case cohort (n  93).-Cauc
(A), DS
tation
01.-Cauc
(A) an
n (mu
D/C R
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June 7, 2011:2317–27 Distinguishing ARVC Mutationsdomains on the proteins constituting the desmosome
(15,16), we next investigated whether missense mutations
identified in ARVC cases might localize preferentially to
critical protein domains compared to control mutations. As
depicted in Figure 6, we identified regions on the linear
Figure 7 Mutation “Hot Spots” Within the Cardiocyte Desmoso
Schematic representation of the desmosome that links neighboring cellular interm
(dashed outline) on DSP and DSG2 are noted. DSC2  desmocolin 2; DSG2  desm
PKP2  plakophilin; PM  plasma membrane.
Figure 6 DSP and DSG2 Mutation “Hot Spots”
Linear topology of DSP and DSG2 with the location of all control missense mutatio
dysplasia (ARVC) case mutations (blue lines, below topology) identified. (A) ARVC
than in control subjects. NT, Z, Y, X, W, V: predicted alpha-helical bundles; A, B, B
quent between residues 24 and 388 of DSG2 (yellow topology) than in control ind
cadherin repeat domains I to IV; IA  intracellular anchor; ICS  intracellular cate
domain; S  signal peptide; TM  transmembrane domain.topology of DSP and DSG2 that were apparent mutation
“hot spots” in which a significantly larger number of
missense case mutations were identified compared with
controls. Specifically, an amino-terminal region of DSP
encompassing 3 of the predicted alpha-helical bundles Z,
filaments through a complex of interacting proteins. Two mutation hotspots
2; DSP  desmoplakin; IF  intermediate filaments; JUP  junction plakoglobin;
ack line, above topology) and arrhythmogenic right ventricular cardiomyopathy/
ions were more frequent between residues 250 and 604 of DSP (red topology)
CT: intermediate filament binding domains. (B) ARVC mutations were more fre-
ls. DTD  desmoglein terminal domain; EA  extracellular anchor; EC1 to EC4 
ding domain; IPL  proline-rich linker; P  propeptide; RUD  repeating unitme
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Distinguishing ARVC Mutations June 7, 2011:2317–27Y, and X (residues 250 through 604) contained 8 of 17
(47%) of the DSP missense mutations found in ARVC
cases compared with 1 of 28 (3.6%) of the DSP missense
mutations found in controls (p  0.0008) (Fig. 6A).
Likewise, the amino-terminal propeptide and cadherin
repeats I to III domains (residues 24 through 388) of
DSG2 demonstrated an overrepresentation of missense
mutations compared with controls (16 of 21 vs. 2 of 20,
p  2.5  105) (Fig. 6B). These mutation hot spots
localize to key regions of the desmosomal macromolec-
ular complex, as demonstrated in Figure 7. Specifically,
ARVC case mutations are more prevalent in a region of
DSP and DSG2 that include, or are closely proximal to,
respective protein binding domains critical to formation
of the desmosome.
Mutations andprimary sequence conservation in plakophilin 2
and desmoglein 2. In an attempt to more clearly define
differences in ARVC case and healthy control missense muta-
tions, we explored possible associations between the location of
missense mutations and the conservation of the primary
sequence across species for each of the ARVC susceptibility
gene products. As demonstrated in Table 3, across the 5
ARVC-associated genes analyzed, mutations identified in
control subjects were more likely to be localized to residues that
were more highly substituted across species (mean 6.71 sub-
stitutions) than ARVC cases (mean 2.85 substitutions, p 
0.0001, z-score  5.61).
Specifically, ARVC case-based missense mutations in
KP2 and DSG2 altered residues that were significantly
ore conserved across species than those missense mu-
ations derived from controls. As shown in Table 4,
mong the 19 PKP2 missense mutations identified in
ontrol subjects, 13 localized to residues that were sub-
tituted in 3 or more species queried (mean 4.13). In
ontrast, among the 23 ARVC case mutations, 11 mu-
ations localized to residues that were not substituted for
ther residues across species, yielding a mean degree of
Sequence Conservation and Missense Mutations in PKP2Table 4 Sequence Conservation and Missense Mutations in PK
Cohort n
Number
0 1 2
Control 19 1 5 0
ARVC 23 11 5 1
Sequence Conservation and Missense Mutations in ARVC GenesTable 3 Sequence Conservation and Missense Mutations in AR
Cohort n
Number o
0 1 2
Control 133 11 19 8
ARVC 81 35 11 6
p  0.0001 (z-score  5.61).
ARVC  arrhythmogenic right ventricular cardiomyopathy/dysplasia; mean  mean number of
f mutations localizing to the 5 ARVC-associated genes analyzed.p  0.0001 (z-score  4.33).
n  total number of mutations localizing to PKP2; other abbreviations as in Table 3.onidentity of 1.65 (p  0.0001, z-score  4.33).
Similarly, 18 of 33 control missense mutations in DSG2
localized to residues with substitutions in more than 5
species (mean 9.15), while 15 of 27 ARVC mutations
localized to nonsubstituted residues (mean 1.96, p 
0.0001, z-score  4.66) (Table 5). For DSP, DSC2,
and TMEM43, we found no relationship, or we were
underpowered to determine an association, between the
degree of species conservation and whether a residue was
altered in an ARVC case or control subject.
Discussion
ARVC genetic test interpretation. Understanding the
background rate of genetic variability is critical to interpret-
ing the results of a genetic test. Recently, the spectrum of
background genetic variation in the genes encoding proteins
implicated in the pathogenesis of another potentially lethal
arrhythmia syndrome, long-QT syndrome, has been eluci-
dated (20). For long-QT syndrome, the background muta-
tion rate for its 3 canonical genes, KCNQ1, KCNH2, and
CN5A, was about 5%. Here, we report an initial back-
round mutation rate, unadjusted for ancestry, in the
nalyzed ARVC susceptibility genes to be approximately
6%, or 3-fold higher than the genetic noise prevalence seen
n long-QT syndrome. This poses several challenges to
nterpreting the ARVC genetic test, as 1 in 6 healthy
ndividuals would meet current criteria for a so-called
ositive ARVC genetic test result, even with proper quali-
cation of these rare “mutations” with the clinically ambig-
ous designation as a “variant of uncertain significance.”
erein, we hope to provide some initial genetic associations
o guide physicians in determining an estimated probability
f pathogenicity following the identification of a rare variant
n an ARVC susceptibility gene.
Given the background rate of mutations in the control
ohort compared with ARVC cases as well as the demon-
cies With Different Residues
Mean3 4 5 >5
3 1 2 7 5.74
2 1 0 3 1.83
enes
cies With Different Residues
Mean3 4 5 >5
10 9 15 61 6.71
5 2 5 17 2.85
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June 7, 2011:2317–27 Distinguishing ARVC Mutationsstrated differences in this signal-to-noise ratio from muta-
tion type (radical vs. missense) and race and ethnicity, we
created a summary of factors we believe alter the likelihood
that a given variant is pathogenic (Fig. 8). First, we observe
that radical mutations (insertions or deletions, splice junc-
tion mutations, and nonsense mutations) are significantly
more prevalent in ARVC cases compared with controls
(49.9% vs. 0.47%, respectively, p  9.8  1044), so an
RVC genetic test result indicating the presence of this
ype of genetic variant has a high likelihood of being
ssociated with ARVC pathogenicity. Notably, such radical
utations constituted the majority (75 of 102, 73.5%) of
enetic alterations identified in mutation-positive ARVC
ases.
If the ARVC genetic test indicates a missense mutation,
e identified 3 associations that might strengthen or
eaken the possibility of ARVC pathogenicity for the
ariant in question. On the basis of our observation that
stensibly healthy Caucasian subjects had a significantly
ower rate of missense mutations than ARVC cases (5.83%
s. 20.6%, respectively, p  0.0009), a rare missense
utation identified in a Caucasian patient is more likely
athogenic than one identified in a non-Caucasian patient.
urthermore, specific amino-terminal regions of DSP and
SG2 may contain mutation “hot spots,” as each was found
Sequence Conservation and Missense Mutations in DSG2Table 5 Sequence Conservation and Missense Mutations in DS
Cohort n
Number
0 1 2
Control 33 1 2 4
ARVC 27 15 2 3
p  0.0001 (z-score  4.66).
n  total number of mutations localizing to DSG2; other abbreviations as in Table 3.
Figure 8 Assessing Likelihood of Pathogenicity
of a Positive ARVC Genetic Test Result
Flow chart of factors influencing likelihood that a given arrhythmogenic right
ventricular cardiomyopathy/dysplasia (ARVC) genetic test–identified mutation is
pathogenic on the basis of comparison of mutations identified in ostensibly
healthy controls versus definite ARVC cases. VUS  variant of undetermined or
uncertain significance.o host significantly more missense mutations in ARVC
ases than in controls (p  0.0008 and p  2.5  105,
espectively). Finally, there were significantly more ARVC
issense mutations involving residues within PKP2 and
SG2 that were highly conserved across species. Given the
bservation that missense mutations in ARVC cases dem-
nstrated a rate of substitution of 1.65 and 1.19 for PKP2
nd DSG2, respectively, compared with 4.13 (p  0.0001)
nd 9.95 (p  0.0001) for control subjects, respectively, the
identification of a missense mutation that involves a highly
conserved residue is more likely pathogenic.
When properly interpreted, ARVC genetic testing ulti-
mately affords the possibility of early detection of preclinical
disease, identification of at-risk family members, and ge-
netic counseling for this sudden death–predisposing disease.
However, because of the potential clinical impact of such a
test, and multiple factors that might influence how and
when a genetic abnormality might manifest as disease,
ARVC genetic testing should not be viewed as a perfectly
binary (yes or no, positive or negative) test. The presence of
a genetic mutation alone cannot override clinical judgment
regarding the diagnosis of ARVC, nor should the absence of
a mutation in the setting of compelling clinical evidence call
the diagnosis into question. Regardless of the strength of
statistical assessment that a mutation is pathogenic, genetic
test results should be viewed as probabilistic and as 1
component of an overall clinical assessment.
Background genetic noise and occult disease. Although
it is possible that occult, undiagnosed ARVC is present in a
small number of the ostensibly healthy volunteers genotyped
in the control cohort, it is highly unlikely that this accounts
for the significant genetic variability found in our control
population. Although most estimates place the prevalence
of ARVC at 1 in 5,000 among the general population (2),
a conservative estimate of 1 in 1,000 would suggest a 50%
chance that only a single subject within the 427-control
cohort has occult ARVC (1). Even if the frequency of
clinically silent ARVC in our cohort were 10-fold higher,
this conservative estimate would constitute approximately
1% of the entire control cohort, ultimately resulting in a
decrease of genetic noise from a 16% to 15% prevalence. In
addition, the relative gene-specific frequency of mutations
in ostensibly healthy subjects supports the hypothesis that
these variants are randomly occurring background genetic
variation. Although the majority (78%) of ARVC case
cies With Different Residues
Mean3 4 5 >5
2 2 4 18 9.15
1 1 2 3 1.96G2
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Distinguishing ARVC Mutations June 7, 2011:2317–27tributed among the ARVC genes in a manner reflective of
the relative size of the gene.
It is also possible that the apparently high rate of
mutations in healthy subjects might be somewhat inflated
for this initial control cohort relative to future studies. One
would expect that genetic interrogation of additional control
subjects would re-encounter some of these unique genetic
variants, while fewer new variants would be discovered. As
per our criteria for mutation designation, a variant identified
in more than 1 healthy subject was not considered a
mutation, so genotyping additional control subjects could
meaningfully reduce the estimated background mutation
rate. One reason the apparent background rate is lower in
the Caucasian subset of controls may be that, relative to
other ancestries, more Caucasian controls have been inter-
rogated genetically previously.
Compound and digenic heterozygosity. A study by Xu et
al. (21) genetically interrogated 198 U.S. and Italian ARVC
cases and identified mutations localizing to PKP2 in roughly
19% of the probands, with 42% of these PKP2-positive
subjects, or 8% of the cohort overall, hosting at least 1
additional mutation in 1 of the ARVC susceptibility genes.
This yield of PKP2 mutations is similar to a Danish ARVC
cohort that demonstrated 8 of 53 subjects (15%) with PKP2
mutations (22). Furthermore, Xu et al. (21) presented a
number of pedigrees of kindred hosting 2 ARVC mutations
in trans, wherein coinheritance of both mutations results in
a more severe clinical phenotype compared to patients
hosting only 1. In their analysis, compound and digenic
heterozygosity accounted for the variable penetrance ob-
served in their pedigrees and led the investigators to
conclude that a single PKP2 mutation may be insufficient to
otentiate clinical disease.
Although we observed a similar prevalence of multiple
utations in ARVC cases overall (7%), this was in the
ontext of a higher percent of PKP2-positive subjects
49.7%, or 39.9% when excluding 3 potential founder
utations). Thus, among the subset of genotype-positive
RVC cases seen in this study, 93% had a single ARVC-
ssociated mutation. This is similar to a recent study by
ressart et al. (23), which identified multiple mutations in
% of ARVC cases. Furthermore, we identified 9 subjects
2%) in our ostensibly healthy control cohort who similarly
osted multiple mutations. Interestingly, a study by Bhui-
an et al. (8) recently found that mutations in DSC2 and
SG2, although less prevalent than mutations in PKP2, also
ccurred in the setting of another mutation in an ARVC-
ssociated gene, perhaps indicating that compound and
igenic heterozygosity might play a role outside of just
KP2 mutations.
Although compound and digenic heterozygosity clearly
lay a large role in explaining some of the incomplete
enetrance and variable expressivity of the disease in ARVC
amilies, we believe that the type and location of the
utation might be similarly important. We found therequency of radical mutations in our control cohort to be w.5%, in comparison with the ARVC case frequency of 43%.
his difference alone provides significant statistical evidence
hat a radical mutation reported on an ARVC genetic test is
ikely pathogenic. Another possibility is that compound and
igenic heterozygosity may play a modulatory role that is
ost salient in families with variable ARVC expression and
ay not play as meaningful a role in dictating disease
enetrance in our cohorts.
tudy limitations. Although this study is the first and
argest systematic examination of the spectrum and preva-
ence of ARVC-associated background genetic variation,
mall sample sizes of both the ARVC case and control
ohorts still represent a limitation, especially considering
ndividual ethnogeographic strata. The observed statistical
ssociations were based on a relatively small sample size
ompared with other similar studies in channelopathic
isease and might be susceptible to sway by addition of a
ew outlier subjects and founder mutation (20). Despite this,
he observed statistical associations appear robust, were
ased on the largest set of controls and one of the largest
ase collections examined to date, and are testable in future
eplication studies. Future studies incorporating additional
henotypically robust ARVC cohorts and thoroughly exam-
ned ostensibly healthy subjects genotyped for the equivalent
f the ARVC genetic test panel will further validate and
xtend the generalizability of these observations.
As previously discussed, normal results on 12-lead elec-
rocardiography, Holter monitoring, and echocardiographic
nalysis were not a prerequisite for inclusion in the control
ohort. Thus, it is possible that a small number of the 69
mutation-positive” controls may have had clinically silent
RVC, and a mutation identified in those subjects could be
alsely considered part of the background genetic variation.
s mentioned earlier, statistically, there should be only 1, at
ost 2, of the 427 control subjects who nevertheless had
RVC. Among these 69 mutation-positive controls, 2 are
ndeed suspicious for ARVC pathogenicity: a subject host-
ng the splice junction IVS5-1GA mutation and one
osting the in-frame DSP-S2843-R2846del and a concom-
tant PKP2-V587I missense mutation. Although we ac-
nowledge the possibility that some mutations among
ontrol subjects may represent incompletely penetrant mu-
ations that may be pathogenic in another patient, for all
ariants to be pathogenic, the average penetrance of these
ariants must be extremely low, as the most conservative
stimate of ARVC in the healthy population is 1 in 1,000.
otably, we cannot exclude the possibility that ARVC
ases, particularly those hosting only 1 ARVC-associated
utation, do not carry a compound mutation in a yet
nknown ARVC susceptibility gene.
onclusions
n the first comprehensive study of genetic variation in
stensibly healthy subjects for ARVC susceptibility genes,
e demonstrate that radical mutations are high-probability
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June 7, 2011:2317–27 Distinguishing ARVC MutationsARVC-associated mutations, whereas rare missense muta-
tions should be interpreted with great caution. A compila-
tion of factors including mutation localization, the conser-
vation of the primary sequence across species, and the race
and ethnicity of the patient influence the probability of
missense mutations truly being the pathogenic biomarker of
disease.
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